Tafasitamab gets positive CHMP opinion in R/R follicular lymphoma
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval
Lymphoma
Indolent B-Cell Lymphomas
Soho Print
Past Issues
SOHO Insider 2025 Print Issue November/December
The SOHO Insider 2025 print issue November/December features an article on a joint pilot R/R CLL/SLL program between SOHO and the Medical Learning
Leukemia News
FDA approves ziftomenib for relapsed or refractory NMP1-mutated AML
The US Food and Drug Administration has approved the menin inhibitor ziftomenib for treatment of relapsed or refractory NMP1-mutated acute myeloid leukemia in
Multiple Myeloma
FDA grants 510(k) clearance to multiple myeloma diagnostic platform
The US Food and Drug Administration (FDA) granted 510(k) clearance to the EXENT® Analyser and Immunoglobulin Isotypes (GAM) Assay, a first-of-its-kind automated platform for
SITC 2025
Multiple Myeloma
IDP-023 demonstrates good safety, efficacy in relapsed or refractory myeloma
In a first-in-human study, IDP-023 demonstrated a promising safety and efficacy profile in patients with relapsed or refractory multiple myeloma, according to findings
Multiple Myeloma
News
Society Updates
Young Investigator Program
SOHO Young Investigator spotlight: Meet Maha Hameed, MD
As a resident physician who is fascinated by hematologic malignancies, Maha Hameed, MD, brings a distinctive combination of scientific intrigue and personal drive
SITC 2025
Leukemia
Acute Lymphoblastic Leukemia
News
Natural killer T-cells show promise for ‘off-the-shelf’ cancer immunotherapy for NHL, ALL
Allogeneic natural killer T cells (NKTs) expressing CD19-specific chimeric antigen receptors (CARs) are well tolerated and can mediate objective responses in non-Hodgkin’s lymphoma
Multiple Myeloma
Video Interviews
Dr. Mateos discusses blenrep/DREAMM-7 trial
Dr. Mateos was the lead investigator on the trial, which investigated belantamab mafodotin (blenrep) with bortezomib and dexamethasone (BVd) versus daratumumab with bortezomib
Leukemia
Acute Myeloid Leukemia
Novel AML product candidate granted orphan drug designation by FDA
Novel product candidate M2T-CD33 (LTI-214) was granted orphan drug designation by the US Food and Drug Administration for the treatment of acute myeloid
Leukemia News
SOHO 2025
Dr. Jabbour discusses investigational menin inhibitor bleximenib
In this interview at the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Elias Jabbour, MD, leukemia professor at the